Advancing Precision Medicine in Singapore Through Structural Genomics

Singapore’s research ecosystem continues to make significant strides in precision medicine, with a new publication highlighting collaborative efforts between Duke-NUS Medical School and other leading institutions. The work introduces SNPdrug3D, an innovative tool that maps genetic variations affecting drug binding across diverse populations.

Understanding Pharmacogenetics and Drug Response

Pharmacogenetics examines how genetic differences influence individual responses to medications. Missense variants, which alter protein sequences, can impact drug efficacy or safety. SNPdrug3D addresses this by integrating structural biology with population genomics data from cohorts like SG10K Health and gnomAD.

The SNPdrug3D Platform and Its Capabilities

Developed by researchers including A.J. Malik and teams from Duke-NUS, A*STAR Bioinformatics Institute, and SingHealth, SNPdrug3D visualizes over 1.17 million variants near drug-binding sites in approximately 6,000 protein-drug complexes. Users can explore impacts on functional regions through sequence and 3D structure views.

The platform supports searches by gene, protein, or drug, flagging potential resistance sites early in development.

Photo by Christina Victoria Craft on Unsplash

Key Findings from the Nature Communications Study

Published in Nature Communications, the study experimentally verified effects of selected variants on drug binding in proteins such as kinases and cytochrome P450 enzymes. A new predictor for CYP family variants outperformed existing tools, achieving high accuracy on annotated and assay-based datasets.

Singapore’s Role in Global Precision Medicine Research

Duke-NUS Medical School, in partnership with SingHealth Duke-NUS Institute of Precision Medicine and other entities, leverages Singapore’s diverse population data to enhance global understanding of pharmacogenetic variation. This aligns with the National Precision Medicine programme, which aims to tailor healthcare based on genetic profiles.

Implications for Drug Development and Clinical Practice

By placing variants in structural context, SNPdrug3D helps preemptively identify sites where population-specific differences might affect drug performance. This supports more inclusive drug design and personalized prescribing strategies, particularly relevant for Asian populations underrepresented in many global datasets.

Photo by freestocks on Unsplash

Future Outlook and Broader Applications

The tool’s integration with Singapore’s precision medicine infrastructure positions the country as a leader in translating genomic insights into clinical tools. Ongoing expansions could include additional drug classes and real-world validation studies.

Collaborative Ecosystem Driving Innovation

Contributions from institutions like the Saw Swee Hock School of Public Health at NUS and national health centres underscore the multidisciplinary approach essential for such advances. These partnerships foster talent development and attract international attention to Singapore’s higher-education and research landscape.